News Releases

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 1, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals , a multi-national pharmaceutical company and leading licensing partner in

Manufacturing of Vicineum drug substance and drug product PPQ batches has been completed Emerging manufacturing data provides strong support for analytical comparability between clinical and commercial material On track to complete BLA submission to the FDA in December 2020 CAMBRIDGE, Mass.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call on Monday, November 9, 2020 at

Meeting outcome confirms the Company’s pathway to a planned MAA submission for Vicineum in early 2021 with anticipated approval in early 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2020-- Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has selected Cardinal Health as its exclusive provider for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H. C.

On-track to complete BLA submission in the US in the fourth quarter of 2020 Entered into a license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China with $12M upfront payment Manufacturing of PPQ campaign drug substance batches has been

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2020-- August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity

Sesen to receive $12 million upfront and $23 million in potential regulatory and tech transfer milestone payments Sesen eligible to receive royalties on net sales in China Sesen to host conference call Friday, July 31 st at 8:00 a.m. EDT CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31,